1. Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

2. Outline of the Program

3. Statistics

4. Pathology

5. Cellular Interactions in the Microenvironment

6. Clinical Significance of the Tumor Microenvironment

13. Preventing Immune Escape Targeting CD30 With Brentuximab Vedotin

18. How Does Immune Checkpoint Blockade work? Blocking PD-1

26. Nivolumab Durability of Response

27. Nivolumab: Treatment-Related AEs

29. Pembrolizumab Durability of Response

31. PD-L1 Expression

32. Phase 2 Data With PD-1 Blockade: Nivolumab

33. Phase 2 Data With PD-1 Blockade: Pembrolizumab

35. ECHELON-1: ABVD vs AVD+BV as Frontline Therapy in Stage III/IV HL

36. Combination Approaches Brentuximab Vedotin + Ipilimumab

37. Conclusions

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)

41. Abbreviations (cont)